Last reviewed · How we verify

NCT04931134

Treatment of Anxiety Disorders With Trigeminal Nerve Stimulation

Active, enrolled NA Last updated 8 April 2025
What this trial tests

NA trial testing Trigeminal nerve stimulation - active in Panic Disorder in 1 participant. Participants enrolled and being followed up; not accepting new ones.

Timeline
7 February 2022
Primary endpoint
31 December 2025
31 January 2026

Quick facts

Lead sponsorDr. Rafael Freire
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment1
Start date7 February 2022
Primary completion31 December 2025
Estimated completion31 January 2026
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Dr. Rafael Freire

Who can join

Adults 18 to 65, any sex, with Panic Disorder or Generalized Anxiety Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary objectives: The primary objective is to ascertain if trigeminal nerve stimulation is an effective treatment with high tolerability for patients with panic disorder, generalized anxiety disorder and social anxiety disorder.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Panic Disorder

Currently open trials in the same condition.

Other Dr. Rafael Freire trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04931134.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing